Erik Klapproth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erik Klapproth has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Kristina Lorenz
Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany
2 shared publications - Paul Saftig
Institut für Biochemie, Christian-Albrechts-Universität zu Kiel, 24098 Kiel, Germany
2 shared publications Peter Mirtschink
Institute for Clinical Chemistry and Laboratory Medicine University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden Dresden Germany
2 shared publications- Ali El-Armouche
Institute of Pharmacology and Toxicology, Technische Universität Dresden, Dresden, Germany
1 shared publication Ali El‐Armouche
Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus Technische Universität Dresden Dresden Germany
1 shared publication- Andreas Dahl
DRESDEN-concept Genome Center (DcGC), Center for Molecular and Cellular Bioengineering (CMCB) Technology Platform, TUD Dresden University of Technology, 01062 Dresden, Germany
1 shared publication
Latest Publications
- Open Access
- 8 October 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (5) , 990-1008
Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction
Background and Purpose: Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses. However, developing selective inhibitors has proven challenging because of cross‐inhibition of other metalloproteases. Protein‐based inhibitors, such as the synthetic ADAM10 prodomain, offer potential for improved selectivity and effectiveness. Experimental Approach: A novel ADAM10 inhibitor, VTH144, was designed by modifying the ADAM10 prodomain and evaluated empirically for selectivity, efficacy and toxicity both in vitro and in vivo and by using machine learning–based modelling. Key Results: AlphaFold3 predictions confirm that the ADAM10 prodomain is highly selective for its protease and identify VTH144 as a unique ADAM10‐inhibiting peptide. Fluorescence resonance energy transfer (FRET) assays verified VTH144 as highly selective for ADAM10, sparing other metalloproteases. In a MI mouse model, we show that VTH144 applied twice, 4 and 48 h after ligation of the left ventricular descending artery (LAD), is highly effective in preserving cardiac function by reducing scar size. VTH144 significantly attenuates ADAM10‐mediated CX 3 CL1 shedding, subsequent neutrophil infiltration into the heart and IL‐1β‐driven systemic inflammation. Importantly, safety pharmacology in naïve mice revealed that ADAM10 inhibition with VTH144 lacks toxic short‐term effects in cardiac, pulmonary, hepatic or renal systems. Conclusions and Implications: Our study highlights the potential of the selective ADAM10 inhibitor VTH144 as a promising therapeutic candidate for improving cardiac function and reducing the risk of heart failure following myocardial infarction.
- 8 October 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (5) , 990-1008
Open AccessLeveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction
Background and Purpose: Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses. However, developing selective inhibitors has proven challenging because of cross‐inhibition of other metalloproteases. Protein‐based inhibitors, such as the synthetic ADAM10 prodomain, offer potential for improved selectivity and effectiveness. Experimental Approach: A novel ADAM10 inhibitor, VTH144, was designed by modifying the ADAM10 prodomain and evaluated empirically for selectivity, efficacy and toxicity both in vitro and in vivo and by using machine learning–based modelling. Key Results: AlphaFold3 predictions confirm that the ADAM10 prodomain is highly selective for its protease and identify VTH144 as a unique ADAM10‐inhibiting peptide. Fluorescence resonance energy transfer (FRET) assays verified VTH144 as highly selective for ADAM10, sparing other metalloproteases. In a MI mouse model, we show that VTH144 applied twice, 4 and 48 h after ligation of the left ventricular descending artery (LAD), is highly effective in preserving cardiac function by reducing scar size. VTH144 significantly attenuates ADAM10‐mediated CX 3 CL1 shedding, subsequent neutrophil infiltration into the heart and IL‐1β‐driven systemic inflammation. Importantly, safety pharmacology in naïve mice revealed that ADAM10 inhibition with VTH144 lacks toxic short‐term effects in cardiac, pulmonary, hepatic or renal systems. Conclusions and Implications: Our study highlights the potential of the selective ADAM10 inhibitor VTH144 as a promising therapeutic candidate for improving cardiac function and reducing the risk of heart failure following myocardial infarction.
- Open Access
- 10 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction
After myocardial infarction the innate immune response is pivotal in clearing of tissue debris as well as scar formation, but exaggerated cytokine and chemokine secretion with subsequent leukocyte infiltration also leads to further tissue damage. Here, we address the value of targeting a previously unknown a disintegrin and metalloprotease 10 (ADAM10)/CX3CL1 axis in the regulation of neutrophil recruitment early after MI. We show that myocardial ADAM10 is distinctly upregulated in myocardial biopsies from patients with ischemia-driven cardiomyopathy. Intriguingly, upon MI in mice, pharmacological ADAM10 inhibition as well as genetic cardiomycyte-specific ADAM10 deletion improves survival with markedly enhanced heart function and reduced scar size. Mechanistically, abolished ADAM10-mediated CX3CL1 ectodomain shedding leads to diminished IL-1β-dependent inflammation, reduced neutrophil bone marrow egress as well as myocardial tissue infiltration. Thus, our data shows a conceptual insight into how acute MI induces chemotactic signaling via ectodomain shedding in cardiomyocytes.
- 10 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Open AccessTargeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction
After myocardial infarction the innate immune response is pivotal in clearing of tissue debris as well as scar formation, but exaggerated cytokine and chemokine secretion with subsequent leukocyte infiltration also leads to further tissue damage. Here, we address the value of targeting a previously unknown a disintegrin and metalloprotease 10 (ADAM10)/CX3CL1 axis in the regulation of neutrophil recruitment early after MI. We show that myocardial ADAM10 is distinctly upregulated in myocardial biopsies from patients with ischemia-driven cardiomyopathy. Intriguingly, upon MI in mice, pharmacological ADAM10 inhibition as well as genetic cardiomycyte-specific ADAM10 deletion improves survival with markedly enhanced heart function and reduced scar size. Mechanistically, abolished ADAM10-mediated CX3CL1 ectodomain shedding leads to diminished IL-1β-dependent inflammation, reduced neutrophil bone marrow egress as well as myocardial tissue infiltration. Thus, our data shows a conceptual insight into how acute MI induces chemotactic signaling via ectodomain shedding in cardiomyocytes.